Philips and LabPON Plan to Create World's Largest Pathology Database of Annotated Tissue Images for Deep Learning

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) and LabPON, the first clinical laboratory to transition to 100% histopathology digital diagnosis, have announced its plans to create a digital database of massive aggregated sets of annotated pathology images and big data utilizing Philips IntelliSite Pathology Solution (1). The database will provide pathologists with a wealth of clinical information for the development of image analytics algorithms for computational pathology and pathology education, while promoting research and discovery to develop new insights for disease assessment, including cancer.

Deep learning algorithms have the potential to improve the objectivity and efficiency in tumor tissue diagnosis. In recent years, 'deep learning' techniques for image analysis have quickly become the state of the art in computer vision and has surpassed human performance in a number of tasks (2). The challenge for executing deep learning techniques is having access to a database with sufficient high volume and high quality data from which to develop the algorithms. As one of the largest pathology laboratories in the Netherlands, LabPON will contribute its repository of approximately 300,000 whole slide images (WSI) they prospectively create each year to the database. This will contain de-identified datasets of annotated cases that are manually commented by the pathologist, and will comprise of a wide variety of tissue and disease types, as well as other pertinent diagnostic information to facilitate deep learning.

"Deep learning focuses on the development of advanced computer programs that automatically understand and digitally map tissue images in considerable detail: The more data available, the more refined the computer analysis will be," said Peter Hamilton, Group Leader Image Analytics at Philips Digital Pathology Solutions. "Together, LabPON and Philips have the competence and skills to realize this."

During a time where the pathologist shortage is mounting and cancer caseloads are increasing (3,4), the accurate diagnosis and grading of cancer has become increasingly complex, placing significant pressures on pathology services. Technologies such as computational pathology, could help pathologists with tools to work in the most efficient way possible.

"The role of the pathologist remains important by making the definitive diagnosis, which has a high impact on the patient's treatment. Software tools could help to relief part of the pathologists' work such as identifying tumor cells, counting mitotic cells or identifying perineural and vaso-invasive growth, as well carrying out measurements in a more accurate and precise way," said Alexi Baidoshvili, pathologist at LabPON. "This ultimately could help to improve the quality of diagnosis and make it more objective."

Next to the development of computational algorithms for diagnostic use, Philips intends to make available the database to research institutions and other partners through its translational research platform. This could enable selected parties to interrogate and combine massive datasets with the goal to discover new insights that ultimately could be translated into new personalized treatment options for patients.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

1. Philips IntelliSite Pathology Solution is CE-IVD marked for use in primary diagnosis. In the United States, the Philips IntelliSite Pathology Solution pending review of a request for de novo classification.
2. Kaiming He Xiangyu et al. Delving Deep into Rectifiers: Surpassing Human-Level Performance on ImageNet Classification. And LeCun, Yann, Yoshua Bengio, and Geoffrey Hinton. "Deep learning." Nature 521, no. 7553 (2015): 436-444.
3. The Royal College of Pathologists, https://www.rcpath.org/profession/workforce/workforce-planning.html, Accessed December 2016.
4. International Agency for Research on Cancer and Cancer Research UK. World Cancer Factsheet. Cancer Research UK, London, 2014.

Most Popular Now

AI Points the Way to Better Doctor-Patie…

A computer analysis of hundreds of thousands of secure email messages between doctors and patients found that most doctors use language that is too complex for their patients to understand...

Open Call DIGITAL-2021-DEPLOY-01-TWINS-H…

The development of digital twins in healthcare (DTH) has progressed substantially, profiting from advances in science and technology. In order to exploit their benefits in view of better prevention approaches...

Mayo Clinic Researchers Use AI, Biomarke…

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients...

Mjog by Livi Launches Remote Monitoring …

Mjog by Livi has launched a remote monitoring tool that will help GPs support and monitor people with depression through messages sent to their smartphones. The latest data from the Office...

Could EKGs Help Doctors use AI to Detect…

Pulmonary embolisms are dangerous, lung-clogging blot clots. In a pilot study, scientists at the Icahn School of Medicine at Mount Sinai showed for the first time that artificial intelligence (AI)...

Computer Model of Blood Enzyme

Membrane-associated proteins play a vital role in a variety of cellular processes, yet little is known about the membrane-association mechanism. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is one such protein with an...

4.5 Million Euros in EU Funding for Saar…

This year, three computer scientists from Saarbrücken were awarded an "ERC Starting Grant" by the European Research Council. This award, endowed with 1.5 million euros each, is among the most...

2022 EU4Health Work Programme Adopted to…

Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for...

Five NHS Trusts in Surrey and Sussex to …

A consortium of NHS trusts that covers a population of circa 1.2 million will gain immediate access to important patient imaging, and will mobilise a regional workforce for patients, following...

Helping Cancer Patients Avoid Excessive …

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of...

The Programme for the Union's Action in …

On 24 March 2021, Regulation (EU) 2021/522 of the European Parliament and of the Council1 was adopted as part of the Multiannual Financial Framework for the 2021-2027 period. That Regulation...

CliniSys Acquires HORIZON Lab Systems an…

CliniSys is announcing the recent acquisition of HORIZON Lab Systems and the combination with Sunquest Information Systems, as CliniSys. This acquisition and Sunquest combination creates one of the world’s...